Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is October 29, 2025, covering a share repurchase executed on October 28, 2025. The transaction was conducted through BNP Paribas SA as part of GSK's existing share buyback programme, established under a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics
The filing details a specific share repurchase event rather than comprehensive financial results. Key metrics for this transaction include:
- Shares Purchased: 320,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,634.00 GBp; highest price paid was 1,655.00 GBp.
- Average Price: Volume-weighted average price paid was 1,644.29 GBp.
- Treasury Holdings: Following this purchase, GSK holds 254,233,344 ordinary shares in treasury.
- Shares in Issue: 4,061,187,442 ordinary shares (excluding treasury shares).
- Voting Rights: Treasury shares represent 6.26% of total voting rights.
Since the programme's inception on September 30, 2025, the company has purchased a total of 6,768,500 ordinary shares. The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the reduction of shares in issue and the increase in treasury stock due to the buyback. The filing does not contain comparative financial data against prior periods or discuss changes in operational performance.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risks are referenced in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and the Q3 Results for 2025. No new guidance or specific management commentary on future outlook is provided in this document.
Investor Verification Checklist
- Verify the total cumulative buyback volume since September 30, 2025 (stated as 6,768,500 shares).
- Confirm the updated treasury share count of 254,233,344 and the resulting 6.26% voting rights attribution.
- Review the non-discretionary agreement terms announced on September 30, 2025, to understand the remaining capacity of the buyback programme.
- Consult GSK's Q3 2025 results and 2024 Form 20-F for comprehensive financial performance and risk factors not detailed in this transaction report.